(Press-News.org) May 19, 2015 - As more infants are born to mothers with dependence on prescription pain medications, the costs of treatment for babies with neonatal abstinence syndrome (NAS) have increased dramatically, suggests a report in the March/April issue of the Journal of Addiction Medicine, the official journal of the American Society of Addiction Medicine. The journal is published by Wolters Kluwer.
"At our institution, costs associated with treating infants with NAS are exponentially higher than the costs associated with infants not affected," write Dr. Kay Roussos-Ross, Assistant Professor of Obstetrics and Gynecology, and colleagues of University of Florida College of Medicine, Gainesville. The researchers believe their findings support recent recommendations to screen or test for substance use in pregnant women.
Rising Treatment Costs for Neonatal Abstinence Syndrome
Nonmedical use of prescription opioid pain medications during pregnancy has increased fivefold since the late 1990s, according to a recent study. Some infants born to women with opioid use disorder will develop neonatal abstinence syndrome--symptoms and complications related to withdrawal from the opioid pain medication to which they were exposed in utero.
Dr. Roussos-Ross and coauthors analyzed cost trends for infants with NAS at one university-affiliated hospital between 2008 and 2011. They identified 160 opioid-exposed newborns: 40 in the first year of the study, 57 in the second year, and 63 in the third year.
Ninety-five of the infants were exposed to "opioid agonist" drugs--methadone or buprenorphine--given during pregnancy to treat the mother's opioid use disorder. The rest were exposed to various "short-acting" prescription opioids taken illicitly by the mother.
In each year, about 50 to 60 percent of opioid-exposed infants developed symptoms of NAS. These infants remained in the hospital after birth for an average of 23 days, compared to the usual post birth stay of one or two days for a normal healthy newborn. For opioid-exposed infants who did not develop opioid withdrawal symptoms, the average hospital stay was about five days.
The total costs of treatment for NAS rose sharply: from about $1.1 million in the first year, to $1.5 million in the second year, to $1.8 million in the third year. These costs were 15 to 16 times higher than of healthy infants.
The rising rates and costs of NAS reflect the ongoing "opioid epidemic" in the United States. The results add to other recent studies showing high costs for treatment for babies born to women with opioid dependence. Those previous studies found that most of the costs are paid by state Medicaid programs.
Dr. Roussos-Ross and coauthors suggest some steps to help address the high financial and human costs associated with neonatal abstinence syndrome. They encourage doctors to be "proactive in screening for drug use, urging women who use chronic opioids to actively engage in family planning and contraception, and encouraging pregnant women who use opioids to seek substance treatment."
The researchers note that although universal screening for drug use during pregnancy has been recommended by major specialty organizations, it is not yet standard practice. They also call for studies to improve the management of NAS and for follow up of evidence that buprenorphine may lead to better treatment outcomes, in comparison to methadone, in the treatment of pregnant women with opioid use disorder.
INFORMATION:
Click here to read "Opioid Use in Pregnant Women and the Increase in Neonatal Abstinence Syndrome: What Is the Cost?"
Article: "Opioid Use in Pregnant Women and the Increase in Neonatal Abstinence Syndrome: What Is the Cost?" (doi: 10.1097/ADM.0000000000000122)
About Journal of Addiction Medicine
The mission of Journal of Addiction Medicine, the official journal of the American Society of Addiction Medicine, is to promote excellence in the practice of addiction medicine and in clinical research as well as to support Addiction Medicine as a mainstream medical specialty. Published quarterly, the Journal is designed for all physicians and other mental health professionals who need to keep up-to-date with the treatment of addiction disorders. Under the guidance of an esteemed Editorial Board, peer-reviewed articles published in the Journal focus on developments in addiction medicine as well as on treatment innovations and ethical, economic, forensic, and social topics.
About The American Society of Addiction Medicine
The American Society of Addiction Medicine is a national medical specialty society of over 3,200 physicians and associated health professionals. Its mission is to increase access to and improve the quality of addiction treatment, to educate physicians, and other health care providers and the public, to support research and prevention, to promote the appropriate role of the physician in the care of patients with addictive disorders, and to establish addiction medicine as a specialty recognized by professional organizations, governments, physicians, purchasers and consumers of health care services and the general public. ASAM was founded in 1954, and has had a seat in the American Medical Association House of Delegates since 1988. Follow ASAM's official Twitter handle: @ASAMorg.
About Wolters Kluwer
Wolters Kluwer is a global leader in professional information services. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.
Wolters Kluwer reported 2014 annual revenues of €3.7 billion. The group serves customers in over 170 countries, and employs over 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on NYSE Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).
For more information about our products and organization, visit http://www.wolterskluwer.com, follow @WKHealth or @Wolters_Kluwer on Twitter, like us on Facebook, follow us on LinkedIn, or follow WoltersKluwerComms on YouTube.
This news release is available in German. Diabetes is one of the scourges of modern society, and the number of cases is rising every year. Already, there are over 380 million diabetics around the world. The International Diabetes Foundation estimates that by 2030, over half a billion people will be suffering from type 2 diabetes. Today, Switzerland has more than 430,000 diabetics, 40,000 of them with type 1 diabetes.
What both type 1 and type 2 diabetes have in common is a dying off of insulin-producing beta cells, which are found on the pancreas. This deprives the ...
This news release is available in French.
Women who were born preterm have a higher risk of giving birth to preterm children, according to a study, published in the journal Obstetrics & Gynecology, from researchers of the CHU Sainte-Justine and the University of Montreal. The researchers demonstrated that 13% of women born before 37 weeks of gestation gave birth prematurely at least once, compared to 9.5% of women born at term. Interestingly, this figure increased to 14% in women born before 32 weeks. "The difference is not alarming considering that according to ...
The DATECAN initiative, Definition for the Assessment of Time-to-event Endpoints in CANcer trials, has published Guidelines for time-to-event end point definitions in breast cancer trials in a recent issue of the Annals of Oncology. Standardized definitions can help researchers to more easily compare the results of clinical trials. The guidelines developed by the DATECAN initiative can help researchers to have a more uniform usage of key endpoints in the design, conduct, and reporting of clinical trials for patients with breast cancer.
DATECAN was initiated by statisticians ...
A new study delineates a sequential pattern of changes in the intestinal microbial population of patients recovering from cholera in Bangladesh, findings that may point to ways of speeding recovery from the dangerous diarrheal disease. The report also finds what appear to be consistent differences between the gut microbial population - also called the microbiota - of individuals in developed countries like the U.S. and those the developing world and provides some of the most complete evidence that the gut microbiota usually return to normal after cholera infection. Their ...
A team led by researchers from UC San Francisco, Organic Health Response, and Microclinic International is reporting results of a study that showed significant benefits of microclinics -- an innovative intervention that mobilized rural Kenyan HIV patients' informal social networks to support their staying in care.
The results showed that microclinics cut in half the normal rate of disengagement from care, which was defined as missing a clinic appointment by 90 days or more, when compared to the control group, and reduced the perceived stigma of HIV by 25 percent within ...
A new study has found that endocrine disrupting chemicals--which can interfere with the actions of hormones in the body--are present in some plastic teethers for babies, and the chemicals can leach out of the products.
Investigators detected significant endocrine activity in 2 of 10 plastic teethers. One teether contained methyl-, ethyl- and propylparaben, while the second contained at least 6 different endocrine disrupting compounds that remain so far unidentified.
"The good news is that most of teethers we investigated did not contain endocrine disruptors. However, ...
An Australian researcher has helped identify the kind of human trial that is most effective for testing Ebola vaccines.
Associate Professor Manoj Gambhir, from Monash University's Department of Epidemiology and Preventive Medicine, is part of the team working on the research. Led by University of Texas Austin researcher Dr Steve Bellan, and in collaboration with the U.S. Centers for Disease Control and Prevention (CDC), the study on the design of CDC's vaccine trial in Sierra Leone is published in The Lancet Infectious Diseases.
Safe and effective vaccines could help ...
Swedish clinicians recently reported the first live birth after uterus transplantation, which was followed by two more uneventful births and another pregnancy that is near term.
In a new Acta Obstetricia et Gynecologica Scandinavica commentary, one of the leaders behind these successes, Professor Mats Brannström, provides insights into how the Swedish uterus transplant project was initiated and its long research journey that spans over more than a decade. The first clinical uterus transplantation trial, which enrolled nine women, was initiated in early 2013 and ...
The anti-epilepsy drug valproate should be avoided whenever possible in women who may become pregnant due to a high risk of malformations and developmental problems in babies who are exposed to the drug before birth.
The guidance comes from a joint task force of the Commission of European Affairs of the International League Against Epilepsy and the European Academy of Neurology. In an Epilepsia paper, the task force notes that it is also important that those women who need valproate to control their seizures are not denied the most effective treatment, as uncontrolled ...
Women with polycystic ovary syndrome, a hormonal disorder that affects 5% to 10% of the female population of fertile age, often experience sexual dysfunction and low self-esteem, but a new study shows that physical resistance training can help.
Women who participated in physical resistance training--which included upper body, lower body, and abdominal exercises--experienced considerable improvements related to sexual function, desire, arousal, lubrication, and pain, as well as decreases in anxiety and depression.
The authors noted that the Journal of Sexual Medicine ...
